SILO
Silo Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.33
−4.90%Year over year
Reported trailing growth
- Revenue
- -25.0%
- EBITDA
- +7.3%
- EBIT
- +14.7%
- EPS
- +22.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -0.1%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.0%
- EBITDA
- +4.6%
- EBIT
- +9.0%
- Net income
- +3.8%
- EPS
- +58.0%
- Free cash flow
- -21.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026